ARMP - הכנסה תפעולית לפני ניכוי פחת armatapharma.com

Armata Pharmaceuticals (ARMP) is actively developing breakthrough phage-based treatments for superbugs. However, geopolitical tensions and logistics disruptions are hindering international trials, resulting in financial losses. A California-based bio-complex with autonomous power supports the production cycle. EBITDA analytics demonstrate operating profit, where 0.00 serves as the current metric, helping to assess the business's resilience to recession.

Armata Pharmaceuticals' high scientific authority in superbug therapy converts into real cash flow from the development of phage preparations. This underlying operating result before depreciation is calculated by stripping daily inflows of non-cash GAAP items, allowing investors to assess the objective rhythm of the business and the efficiency of fundamental operations regardless of quarterly accounting adjustments.